NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, Forecast & News

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.22) EPS for the quarter, topping the Zacks' consensus estimate of ($0.24) by $0.02. The biotechnology company had revenue of $5.61 million for the quarter, compared to the consensus estimate of $7.05 million. Progenics Pharmaceuticals had a negative return on equity of 91.96% and a negative net margin of 311.63%. View Progenics Pharmaceuticals' Earnings History.

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Progenics Pharmaceuticals.

3 Wall Street analysts have issued 1 year price targets for Progenics Pharmaceuticals' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 132.6% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

Press coverage about PGNX stock has been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a news impact score of -3.4 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Progenics Pharmaceuticals.

Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Imax (IMAX), Novavax (NVAX), Cara Therapeutics (CARA), Opko Health (OPK), Portola Pharmaceuticals (PTLA) and Dynavax Technologies (DVAX).

Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Farallon Capital Management LLC (9.55%), Eagle Asset Management Inc. (5.21%), State Street Corp (5.09%), Broadfin Capital LLC (3.54%), Geode Capital Management LLC (1.35%) and CNH Partners LLC (1.22%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View Institutional Ownership Trends for Progenics Pharmaceuticals.

PGNX stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., Bank of New York Mellon Corp, UBS Group AG, New York State Common Retirement Fund, Arizona State Retirement System, Rafferty Asset Management LLC, Public Sector Pension Investment Board and Principal Financial Group Inc.. View Insider Buying and Selling for Progenics Pharmaceuticals.

PGNX stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, CNH Partners LLC, Farallon Capital Management LLC, State Street Corp, Alliancebernstein L.P., Bank of America Corp DE, ARP Americas LP and Ikarian Capital LLC. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc and Velan Capital, LP. View Insider Buying and Selling for Progenics Pharmaceuticals.

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PGNX stock can currently be purchased for approximately $5.16.

Progenics Pharmaceuticals has a market capitalization of $445.93 million and generates $15.62 million in revenue each year. The biotechnology company earns $-67,660,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe.View Additional Information About Progenics Pharmaceuticals.

The official website for Progenics Pharmaceuticals is http://www.progenics.com/.

Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]